AAO 2022

START-END Oct 1, 2022 from 9:20 AM to 9:25 AM CDT
Title: A 2-year Phase 1b/2 Study of the Safety and Tolerability of Tinlarebant in Adolescent STGD1
Subjects: Interim Findings Abstract #: 30071744
Presenting Author: John Grigg, MBBS
Section: Section X, Late Breaking Developments, Part II
Supporting Materials
McCormick Place - Arie Crown

Join our mailing list.


Sign up to receive important updates and news from Belite Bio